RxDoctor Payments DataLook up a doctor →

Andrew Zadeh, MD

Clinical Cardiac Electrophysiology · West Hollywood, CANPI 1033305305

Payments from drug & device makers

$503,883in general payments, 2019–2025

Across 835 payments — averaging $603.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$255K
  • Impulse Dynamics (USA) Inc.$109K
  • Medtronic$104K
  • Boston Scientific$16K
  • Philips North America LLC$9K
  • Biosense Webster, Inc.$5K
  • plus $5K from 17 others

What the payments were for

  • Consulting fees$13,28432%
  • Speaking & faculty fees$4,10010%
  • Travel & lodging$4,71111%
  • Food & beverage$19,01146%
  • Education$1500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$503,883 in reported general payments places this provider in the 90th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$250,830
Medicare patients
1,050
Services billed
3,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$75,285
XareltoRivaroxaban16$23,765
FarxigaDapagliflozin Propanediol20$19,290
MultaqDronedarone Hcl13$14,132
Metoprolol Succinate75$1,806
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$747
Flecainide Acetate20$589
Valsartan19$370
Atorvastatin Calcium31$305
Hydralazine Hcl13$281
Amlodipine Besylate24$255
Rosuvastatin Calcium24$250
Carvedilol22$197
Nifedipine ErNifedipine11$159
Lisinopril15$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$75,28562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →